384 related articles for article (PubMed ID: 24439462)
1. Refractive changes after pharmacologic resolution of diabetic macular edema.
Deák GG; Lammer J; Prager S; Mylonas G; Bolz M; Schmidt-Erfurth U;
Ophthalmology; 2014 May; 121(5):1054-8. PubMed ID: 24439462
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
Sheth S; Rush R; Natarajan S; Gillies M
Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
[TBL] [Abstract][Full Text] [Related]
4. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab.
Jeon S; Lee WK
Retina; 2014 Aug; 34(8):1606-11. PubMed ID: 24553409
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU
Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
Kim M; Lee P; Kim Y; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R
Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery.
Takamura Y; Kubo E; Akagi Y
Ophthalmology; 2009 Jun; 116(6):1151-7. PubMed ID: 19376589
[TBL] [Abstract][Full Text] [Related]
16. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
[TBL] [Abstract][Full Text] [Related]
19. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
Sonoda Y; Arimura N; Shimura M; Sakamoto T
Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
[TBL] [Abstract][Full Text] [Related]
20. Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema.
Sonoda S; Sakamoto T; Yamashita T; Otsuka H; Shirasawa M; Kakiuchi N; Uchino E; Terasaki H; Kawano H
Invest Ophthalmol Vis Sci; 2014 Jun; 55(6):3979-85. PubMed ID: 24906857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
